Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Launois R, Le Moine J, Uzzan B, Fiestas Navarette LI, Benamouzig R. Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical andguaiac-based fecal occult blood tests for colorectal cancer screening. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):978-89. doi: 10.1097/MEG.0000000000000160
Hartman M, Bolton E, Fehnel SE. Accounting for age differences on the Wisconsin Card Sorting Test: decreased working memory, not inflexibility. Psychol Aging. 2001 Sep 1;16(3):385-99.